BioVaxys Raises $1.9M to Advance Novel Immunotherapy Pipeline

NEW YORK, NY – November 19, 2025

BioVaxys Technology Corp., a clinical-stage biopharmaceutical company, has completed a non-brokered private placement raising approximately $1.92 million CAD. The funding will be critical in advancing the company’s innovative immunotherapy programs, with a focus on its proprietary DPX™ platform and its applications in cancer treatment and allergy management. The raise comes at a time when biotech financing is increasingly difficult to secure, making this a significant step for the company.

Funding & Strategic Direction

The financing, conducted through the issuance of approximately 11.31 million units, priced at $0.17 each, provides a much-needed boost to BioVaxys’ research and development efforts. Each unit comprises one common share and one share purchase warrant, offering potential future value to investors. The company’s CEO, James Passin, demonstrated confidence in the company's future by participating in the placement with a personal investment of $252,379.96. The funds are earmarked for a multi-pronged strategy: bolstering preclinical studies, particularly for its food allergy program at McMaster University; supporting data analysis for its lead cancer asset, MVP-S; and filing new patents. A portion will also be dedicated to exploring potential out-licensing opportunities for MVP-S in different cancer types.

“This financing allows us to accelerate our pipeline and further validate the potential of our DPX™ platform,” said a source close to the company. “The focus is on de-risking the assets and creating value for shareholders.”

DPX™ Platform & Pipeline Progress

At the heart of BioVaxys’ innovation is its DPX™ immune-educating technology platform. This lipid-based delivery system is designed to stimulate a robust and sustained immune response by attracting antigen-presenting cells. Unlike traditional vaccine delivery methods, DPX™ doesn’t rely on releasing its payload immediately, but rather focuses on educating the immune system for a more targeted and durable effect. This approach could be particularly valuable in treating complex diseases like cancer and allergies, where generating a specific and long-lasting immune response is crucial.

The company’s lead program, MVP-S, is currently in Phase IIB clinical development for Relapsed-Refractory Diffuse Large B Cell Lymphoma and platinum-resistant Ovarian Cancer. Early data has shown promising results, with some patients exhibiting positive responses, prompting the company to actively seek a partner for further development. Beyond MVP-S, BioVaxys is also advancing programs targeting food allergies, respiratory syncytial virus (RSV), and influenza, showcasing the versatility of the DPX™ platform. While the company is making progress across multiple fronts, the competitive landscape in immunotherapy and allergy treatment is intense. The company faces competition from established pharmaceutical giants and other biotech firms developing novel therapies. “Differentiation will be key,” notes an industry analyst. “BioVaxys needs to demonstrate clear advantages in terms of efficacy, safety, and cost-effectiveness.”

Navigating a Challenging Biotech Climate

The recent financing comes at a time when the biotech industry is facing significant headwinds. Funding for early-stage companies has become more difficult to secure, and investors are increasingly cautious about taking on risk. This challenging environment underscores the importance of BioVaxys’ ability to demonstrate progress and deliver tangible results. The company’s current market capitalization of approximately $7.19 million CAD reflects these challenges, and it will need to consistently prove its ability to execute its pipeline and generate value for shareholders. The company’s reliance on the Listed Issuer Financing Exemption (LIFE) demonstrates an effort to streamline the fundraising process. The LIFE exemption, introduced to provide easier access to capital for listed issuers, allows BioVaxys to issue securities without a full prospectus, but requires compliance with certain eligibility criteria and disclosure requirements. The company has also demonstrated an understanding of the regulatory landscape by complying with the requirements of the LIFE exemption, ensuring transparency and investor protection.